Since human papillomavirus (HPV) vaccine was first introduced for females in the United
States in 2006, vaccination policy has evolved as additional HPV vaccines were licensed …

The current prevention efforts for STIs, HIV and viral hepatitis in the WHO European Region,
especially in the Central and Eastern subregions, are hindered by healthcare disparities …

Patients with breast tumors that do not express the estrogen receptor, the progesterone
receptor, nor Her-2/neu are hence termed “triple negatives”, and generally have a poor …

Introduction Since 2006, human papillomavirus vaccine has been recommended for young
females in the US This study aimed to compare cervical cancer incidence among young …

Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …

The human papillomavirus (HPV) family comprises more than 170 different types that
preferentially infect the mucosa of the genitals, upper-respiratory tract, or the skin. The 'high …

Efforts are being made to scale up human papillomavirus (HPV) vaccination for adolescent
girls in India. Bivalent and quadrivalent HPV vaccines were licensed in the country in 2008 …

Prophylactic vaccines have been found to be highly effective in preventing infection and pre-
invasive and invasive cervical, vulvovaginal and anal disease caused by the vaccine types …

Persistent high-risk human papillomavirus (HPV) infection is the pivotal cause of cervical
carcinogenesis. HPV types distribution varies greatly by region, and its long-term changes of …

Human papillomaviruses (HPVs) are the causative agents of human neoplasias such as
warts and cancers. There are∼ 19 HPV types associated with cancers, which has made it …